Follow-up After Adrenalectomy
For patients undergoing adrenalectomy, assess steroid replacement needs on postoperative day 1 with morning cortisol testing, perform biochemical evaluation at 3 months for aldosterone-producing adenomas, and reserve routine steroid replacement only for patients with Cushing syndrome or bilateral adrenalectomy.
Steroid Replacement Guidelines
Immediate Postoperative Assessment (Day 1)
The decision to initiate steroid replacement depends on the indication for surgery:
For non-cortisol secreting tumors:
- Measure morning serum cortisol on postoperative day 1 1
- If cortisol ≥10 μg/dL: No steroid replacement needed—no patients in this group develop adrenal insufficiency symptoms 1
- If cortisol <10 μg/dL: Three management approaches are safe 1:
- Clinical symptoms alone (spares most patients from unnecessary steroids)
- Selective ACTH stimulation testing (75% show adequate response despite low cortisol)
- Empirical replacement based on cortisol alone (most conservative but treats many unnecessarily)
For Cushing syndrome (overt or subclinical):
- Empirical perioperative glucocorticoid replacement is mandatory 2
- Alternative: Use postoperative day 1 morning cortisol or cosyntropin stimulation testing to determine replacement need 2
For bilateral adrenalectomy:
- Lifelong steroid replacement is required 3
Critical Caveat for Primary Aldosteronism
Perform ACTH stimulation testing in all PA patients post-adrenalectomy 4. This population has a surprisingly high incidence of postoperative adrenal insufficiency:
- 27% develop AI after unilateral adrenalectomy 4
- Severe AI (stimulated cortisol ≤13.5 μg/dL) requires median 353 days of replacement 4
- Moderate AI (stimulated cortisol 13.5-17 μg/dL) requires median 74 days 4
- Risk of adrenal crisis: 6.9 per 100 patient-years 4
The 2025 Endocrine Society guidelines recommend dexamethasone suppression testing preoperatively for PA patients with adenomas to identify autonomous cortisol secretion, as this predicts postoperative glucocorticoid insufficiency 5.
Biochemical Follow-up Timing
For Aldosterone-Producing Adenomas
Schedule biochemical evaluation at 3 months postoperatively 6. This timing is critical because:
- Plasma aldosterone concentration drops immediately (presurgery: 407 pg/mL → 1 month: 90 pg/mL) 6
- Active renin concentration does NOT increase until 3 months (presurgery: 4.43 → 1 month: 4.87 → 3 months: 11.3 pg/mL) 6
- 14% of patients are reclassified into different biochemical outcomes between 1 and 3 months 6
- Only 3% change classification between 3 and 6 months 6
- Hypokalemia resolves in 82% by 1 month and 100% by 3 months 6
Blood Pressure Outcomes
Blood pressure and antihypertensive medication requirements stabilize early 7:
- Strongest decrease occurs in the first postoperative month
- Stable course from 4-6 months through 12 months
- BP-related outcomes can be assessed reliably at 4-6 months, questioning the need for routine long-term follow-up 7
Duration of Steroid Replacement
For patients requiring replacement after cortisol-producing adenoma resection, predictors of longer duration include 8:
- High midnight serum cortisol levels preoperatively (reflects persistent HPA axis suppression)
- Presence of lumbar compression fracture (indicates severity and chronicity of hypercortisolism)
- Median replacement duration: 12 months (range 5-24 months) 8
Who Does NOT Need Steroid Replacement
Patients undergoing unilateral adrenalectomy for non-Cushing adrenal tumors do not require postoperative steroid replacement 3. In a series of 331 adrenalectomies, zero cases of acute adrenocortical insufficiency occurred in the 274 patients who did not receive replacement 3.
Practical Algorithm
Preoperative: Screen PA patients with adenomas for autonomous cortisol secretion using 1-mg dexamethasone suppression test (cortisol >1.8 μg/dL suggests ACS) 5
Postoperative Day 1: Measure morning cortisol
- ≥10 μg/dL → No replacement
- <10 μg/dL → Consider ACTH stimulation test or monitor symptoms
3 Months: Biochemical evaluation for PA (aldosterone, renin, potassium, ARR)
4-6 Months: Assess blood pressure outcomes and antihypertensive needs
Ongoing: For patients on replacement, monitor for recovery based on preoperative cortisol severity markers